A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer

Table 2 Summary of ER, PgR and Ki67 labeling index data

	Fulvestrant 500 mg	Fulvestrant 500 mg + anastrozole 1 mg	Anastrozole 1 mg
ER
n	35	31	37
Pre-treatment mean H-score	187.7	184.2	192.2
Post-treatment mean H-score	111.9	115.8	164.2
Change (post-treatment), % (SEM)	-41 (4)	-39 (5)	-13 (4)
Comparison versus baseline	P = 0.0001	P = 0.0001	P = 0.0034
PgR
n	33	28	33
Pre-treatment mean H-score	145.7	141.7	157.6
Post-treatment mean H-score	97.9	81.1	93.8
Change (post-treatment), % (SEM)	-34 (6)	-45 (7)	-37 (6)
Comparison versus baseline	P = 0.0001	P = 0.0001	P = 0.0001
Ki67
n	35	31	37
Pre-treatment mean index	17.1	17.8	16.2
Post-treatment mean index	4.2	3.3	2.6
Change (post-treatment), % (SEM)	-75 (9)	-81 (7)	-85 (5)
Comparison versus baseline	P = 0.0001	P = 0.0001	P = 0.0001

ER, estrogen receptor; PgR, progesterone receptor; SEM, standard error of the mean.

ISSN: 1465-542X